The Essentials
- What hematological cancer treatment looks like: Leukemia and lymphoma are treated with long courses of intravenous chemotherapy, monoclonal antibodies, targeted biologics and supportive infusions, often spanning months to years. Most of these treatments can be delivered as outpatient care once the initial intensive phase is complete.
Why comfort and privacy are clinical, not cosmetic: Blood cancer patients are usually immunocompromised. Crowded hospital corridors, shared infusion bays, and long waits in busy waiting rooms increase the risk of infection that supportive care is specifically designed to prevent. Quiet, controlled and private settings are part of the clinical picture, not a luxury upgrade.
- Where IV One fits in: IV One Infusion Centre administers hematological oncology treatments and supportive infusions on referral from your treating hematologist. We do not diagnose or design your plan; we deliver it faithfully in a calm, low-footfall outpatient setting in IV One center.
What Hematological Oncology Means
Hematological oncology is the branch of cancer medicine that treats cancers of the blood, bone marrow and lymphatic system. It is a distinct specialty from solid tumor oncology because the biology, treatment regimens and supportive care needs are different.
The three broad categories are leukemia, lymphoma and multiple myeloma. According to the American Society of Hematology, these blood cancers together account for a significant share of all cancer diagnoses worldwide, and most are now treated with combinations of chemotherapy, monoclonal antibodies, targeted biologics and supportive infusions.
Treatment is rarely a single course. Many patients move through phases of induction, consolidation and maintenance, then either continue long term therapy or move into surveillance with intermittent treatment as needed.
The Main Categories of Leukemia and Lymphoma
A short orientation helps families understand what their treating hematologist is planning.
Leukemia
Leukemia is cancer of the blood and bone marrow. It is grouped by speed (acute or chronic) and by cell type (myeloid or lymphoid). The four main categories are acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML). Treatment intensity varies widely between them.
Lymphoma
Lymphoma is cancer of the lymphatic system and is grouped into Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). NHL includes diffuse large B cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma and many other subtypes. Most modern lymphoma regimens combine chemotherapy with a monoclonal antibody such as rituximab.
Multiple myeloma and related conditions
Multiple myeloma is a cancer of plasma cells in bone marrow. It is often discussed alongside leukemia and lymphoma because the supportive care needs and infusion regimens overlap significantly.
How IV Therapy Fits into Modern Blood Cancer Treatment
Most leukemia and lymphoma regimens combine more than one treatment class. Intravenous infusions sit at the center of nearly all of them.
Chemotherapy backbone
Many hematological cancers are treated with multi-agent chemotherapy regimens such as R-CHOP, ABVD, FCR and bendamustine-based protocols. These are delivered as cycles every two to four weeks.
Monoclonal antibodies and immunotherapy
Anti-CD20 antibodies such as rituximab and obinutuzumab transformed into lymphoma and CLL treatment. Checkpoint inhibitors such as pembrolizumab and nivolumab have changed the outlook for Hodgkin lymphoma. Most are given as outpatient infusions.
Targeted biologics
Brentuximab vedotin in Hodgkin lymphoma, polatuzumab vedotin in DLBCL, daratumumab in multiple myeloma and many others give modern hematology its precision edge. Many are delivered intravenously, with some now available subcutaneously.
Supportive infusions
Blood transfusions, immunoglobulin replacement, growth factor support, hydration and electrolyte correction are core to the patient experience and often required between cycles.
Common IV Treatments and Supportive Infusions for Blood Cancer Patients
The table below summarizes the main IV treatments and supportive infusions used in hematological oncology. This is a reference, not a treatment plan. Your hematologist decides what you receive and when.
| Treatment or Infusion | Purpose | Typical Session Length | Common Use Cases |
| Chemotherapy combinations | Destroy cancer cells, achieve remission | 1 to 6 hours | DLBCL, follicular lymphoma, CLL, AML consolidation |
| Anti CD20 monoclonal antibodies (rituximab, obinutuzumab) | Mark B cell cancers for immune destruction | 2 to 6 hours initially, shorter from cycle 2 | NHL, CLL |
| Targeted biologics (brentuximab vedotin, polatuzumab vedotin, daratumumab) | Block specific molecular targets in the cancer | 30 minutes to 4 hours | Hodgkin lymphoma, DLBCL, multiple myeloma, ALL |
| Checkpoint inhibitor immunotherapy (Nivolumab, Pembrolizumab) | Activate immune system against cancer | 30 to 90 minutes | Relapsed Hodgkin lymphoma, selected others |
| IVIG (intravenous immunoglobulin) | Replace antibodies in patients with hypogammaglobulinaemia | 2 to 4 hours | CLL, multiple myeloma, post stem cell transplant |
| Growth factor support (G-CSF) | Reduce neutropenia between chemotherapy cycles | 5 to 15 minutes | Higher risk chemotherapy regimens |
| Bone modifying agents (zoledronic acid, denosumab) | Strengthening bone, prevent skeletal events | 15 to 30 minutes | Multiple myeloma, bone involvement |
Why Comfort and Privacy Matter More for Blood Cancer Patients
Comfort and privacy are often described as patient experience benefits. For blood cancer patients they are also clinical.
Immunocompromised status and infection risk
Both the disease and the treatment compromise the immune system. The Leukemia and Lymphoma Society lists infection as one of the most common and dangerous complications during treatment. Time spent in busy hospital corridors and shared waiting rooms is time spent in a higher exposure environment.
Long treatment courses
A first line rituximab regimen typically runs six to eight cycles, with maintenance every two to three months for up to two years. Hodgkin and DLBCL regimens span months. Multiple myeloma is treated as a chronic disease that requires ongoing therapy. A treatment day repeats many times, and the cumulative effect of where it is delivered matters.
Frequency of supportive visits
Blood counts often require transfusions between cycles. IVIG replacement is monthly for many CLL and myeloma patients. Add chemotherapy and biologic days and the calendar can fill quickly. Predictable scheduling at a single center eases the logistical load.
The importance of having family close
Long treatment days are easier with a partner, parent or close friend at your side. Hospital wards limit this. Private infusion centers are designed to keep family close.
Specialized Supportive Care for Blood Cancer Patients
Blood cancer patients often need specific supportive infusions that are less common in solid tumor care.
Blood product transfusions
Red cell transfusions for treatment related to anemia and platelet transfusions for thrombocytopenia are core to safe treatment.
Intravenous immunoglobulin (IVIG)
Patients with CLL or multiple myeloma often develop hypogammaglobulinemia, meaning their antibody production drops to dangerous levels. Monthly IVIG infusions restore antibody levels and significantly reduce infection rates.
Growth factor support
Granulocyte colony stimulating factor (G CSF) injections prevent or shorten neutropenia after chemotherapy.
Hydration and electrolyte replacement
Many hematology regimens place strain on kidneys and electrolyte balance. Scheduled hydration and replacement infusions protect both.
Bone strengthening infusions
Multiple myeloma in particular causes bone weakness and skeletal events. Zoledronic acid or denosumab infusions are standard.
Hematological Oncology Care in Saudi Arabia
Saudi Arabia has expanded hematological oncology capacity significantly under Vision 2030. National cancer centers now offer modern combination regimens including anti CD20 antibodies, targeted biologics, checkpoint inhibitors and selected cell therapies, in line with NCCN and ESMO guidelines.
Tertiary care for induction and complex cases
Acute leukemia induction, allogeneic stem cell transplant and CAR T cell therapy remain centralized at tertiary cancer centers in Riyadh and a small number of other cities.
The role of outpatient infusion for the long tail
Once a patient is past the most intensive phase, much of hematological oncology care is delivered as outpatient infusion. Maintenance rituximab, IVIG replacement, supportive transfusions, hydration and growth factor support are all suitable for outpatient settings.
Dedicated infusion centers are easing pressure
As Riyadh’s tertiary cancer centers operate at capacity, accredited outpatient infusion centers are taking on more of the long term treatment load on referral, freeing hospital bed capacity and giving patients shorter waits and more privacy.
How IV One Supports Leukemia and Lymphoma Patients
IV One Infusion Center is Saudi Arabia’s first dedicated medical intravenous therapy center, Riyadh. We do not diagnose blood cancer, and we do not design your treatment plan, that work belongs to your treating hematologist. What we do is administer the treatment and supportive infusions they have prescribed, with hospital grade standards and a setting built around your comfort. Meet our clinical team before you commit.
A faithful extension of your hematologist’s plan
We administer your prescribed regimen exactly as ordered, with every preparation reviewed by an oncology trained pharmacist and every infusion delivered by a chemotherapy certified nurse.
Infection control by design
Controlled access, private suites, low footfall and stringent infection control protocols reduce avoidable exposure for immunocompromised patients.
Private suites for long treatment days
Calm lighting, comfortable seating, refreshments and a companion welcome in the room. A treatment day that runs four hours feels very different in a private suite than in a shared bay.
A single, consistent care team
You will know the name and number of your coordinator from your first call. The same chemotherapy certified nurses see you through your treatment course.
Specialized supportive infusions under one roof
We administer IVIG, blood products on referral, growth factor support, bone modifying agents, hydration and electrolyte replacement alongside your primary regimen, cutting down repeat visits. Browse the full scope on our conditions we treat page.
Direct coordination with your treating hematologist
We share your cycle reports, vitals and any clinical observations with your hematologist the same day, so your plan stays under their control while the delivery stays with us.
Frequently Asked Questions
Can leukemia and lymphoma be treated as outpatient care?
What is rituximab, and how is it given?
What is IVIG and why might I need it?
Are blood transfusions delivered at IV One center?
Is it safe for an immuno-compromised patient to receive treatment in an outpatient infusion center?
How long does treatment for lymphoma or leukemia last?
Will my hematologist still manage my care if I receive infusions at IV One?
Can my family stay with me during infusion sessions?
Key Takeaways
Leukemia, lymphoma and related blood cancers are treated with long courses of intravenous chemotherapy, monoclonal antibodies, targeted biologics and supportive infusions, much of which are suitable for outpatient delivery.
Comfort, privacy and infection control are clinical considerations for blood cancer patients, not cosmetic ones. Immunocompromised patients benefit from low footfall and private suites.
Specialized supportive infusions such as IVIG, growth factor support and bone-modifying agents are central to safe and effective treatment.
Saudi Arabia’s tertiary cancer centers deliver world-standard care for induction and complex phases, while accredited outpatient infusion centers now play a growing role in the long-term treatment phase.
IV One Infusion Centre administers oncology infusion therapy, including hematological oncology treatments and supportive infusions, on referral from your treating hematologist, in a calm, accredited outpatient setting in Riyadh.
Speak to IV One
If you or someone in your family is being treated for leukemia, lymphoma or another blood cancer and your hematologist has prescribed IV treatment or supportive infusions, our team can administer them for you in Riyadh. We will coordinate directly with your haematologist, fit sessions around your existing treatment days, and look after you in a private, infection-conscious setting from start to finish.
Get in touch with the IV One team to start the conversation.
Sources and references: American Cancer Society, American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), Leukemia and Lymphoma Society (LLS), National Comprehensive Cancer Network (NCCN), Saudi Cancer Registry, Saudi Food and Drug Authority (SFDA), Saudi Ministry of Health (MOH), Saudi Central Board for Accreditation of Healthcare Institutions (CBAHI), Council of Health Insurance (CHI).